A team led by researchers at the NHLBI are testing the efficacy of measuring ddcfDNA in blood as a biomarker of chronic rejection for lung transplants.
Nucleosome organization appears to follow two principles, according to the researchers' analyses of three different cell types.
Participants in the pilot will begin developing the capabilities required for the planned data commons, including making data transparent and interoperable.
The funding will support research projects using data from the Trans Omics for Precision Medicine program to uncover disease pathology.
Eleven new studies from the NHLBI NextGen Consortium show different uses for iPSCs to study polygenetic diseases across various systems in the human body.
The partners are developing an assay to detect minimal residual disease in leukemia patients, for use with Sellas' investigational AML drug.
Funded projects will support the agency's Trans Omics for Precision Medicine program, which is focused on heart, lung, blood, and sleep disorders.
The CCHMC will act as the coordinating center for members of the NHLBI's Cardiovascular Development Consortium and Pediatric Cardiac Genomics Consortium.
The center has already sequenced and analyzed 1,500 human genomes for the TOPMed program and will expand this effort with the new funding.
The funding will support the Broad's sequencing of 20,000 individuals as part of the NHLBI's Trans-Omic for Precision Medicine program.
The Wall Street Journal looks into FamilyTreeDNA's handling of genetic genealogy searches by law enforcement.
In a point-counterpoint in the Boston Globe, researchers discuss the potential of gene editing to prevent Lyme disease, but also the pitfalls of doing so.
MIT's Technology Review reports that researchers hope to develop a CRISPR-based pain therapy.
In Science this week: atlas of malaria parasites' gene expression across their life cycles, and more.